Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

402 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Entrectinib: a potent new TRK, ROS1, and ALK inhibitor.
Rolfo C, Ruiz R, Giovannetti E, Gil-Bazo I, Russo A, Passiglia F, Giallombardo M, Peeters M, Raez L. Rolfo C, et al. Among authors: giovannetti e. Expert Opin Investig Drugs. 2015;24(11):1493-500. doi: 10.1517/13543784.2015.1096344. Epub 2015 Oct 12. Expert Opin Investig Drugs. 2015. PMID: 26457764 Review.
Thymidylate synthase inhibitors for non-small cell lung cancer.
Galvani E, Peters GJ, Giovannetti E. Galvani E, et al. Among authors: giovannetti e. Expert Opin Investig Drugs. 2011 Oct;20(10):1343-56. doi: 10.1517/13543784.2011.617742. Epub 2011 Sep 9. Expert Opin Investig Drugs. 2011. PMID: 21905922 Review.
Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects.
Bronte G, Rolfo C, Giovannetti E, Cicero G, Pauwels P, Passiglia F, Castiglia M, Rizzo S, Vullo FL, Fiorentino E, Van Meerbeeck J, Russo A. Bronte G, et al. Among authors: giovannetti e. Crit Rev Oncol Hematol. 2014 Feb;89(2):300-13. doi: 10.1016/j.critrevonc.2013.08.003. Epub 2013 Aug 28. Crit Rev Oncol Hematol. 2014. PMID: 24041630
Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors.
Rolfo C, Giovannetti E, Hong DS, Bivona T, Raez LE, Bronte G, Buffoni L, Reguart N, Santos ES, Germonpre P, Taron M, Passiglia F, Van Meerbeeck JP, Russo A, Peeters M, Gil-Bazo I, Pauwels P, Rosell R. Rolfo C, et al. Among authors: giovannetti e. Cancer Treat Rev. 2014 Sep;40(8):990-1004. doi: 10.1016/j.ctrv.2014.05.009. Epub 2014 Jun 6. Cancer Treat Rev. 2014. PMID: 24953979 Free article. Review.
On the pharmacogenetics of non-small cell lung cancer treatment.
Santarpia M, Rolfo C, Peters GJ, Leon LG, Giovannetti E. Santarpia M, et al. Among authors: giovannetti e. Expert Opin Drug Metab Toxicol. 2016;12(3):307-17. doi: 10.1517/17425255.2016.1141894. Epub 2016 Feb 17. Expert Opin Drug Metab Toxicol. 2016. PMID: 26761638 Review.
The potential of neurotrophic tyrosine kinase (NTRK) inhibitors for treating lung cancer.
Passiglia F, Caparica R, Giovannetti E, Giallombardo M, Listi A, Diana P, Cirrincione G, Caglevic C, Raez LE, Russo A, Rolfo C. Passiglia F, et al. Among authors: giovannetti e. Expert Opin Investig Drugs. 2016;25(4):385-92. doi: 10.1517/13543784.2016.1152261. Epub 2016 Feb 24. Expert Opin Investig Drugs. 2016. PMID: 26881293 Review.
402 results